To the Editor:
We are writing to express our serious concerns regarding the recent publication of the so-called “new multisociety guidance” on the perioperative management of glucagon-like peptide-1 receptor agonists (GLP-1 RAs). While presented as an authoritative directive, this guidance1 lacks clarity, scientific transparency and practical applicability in real-world surgical settings.
Given the significant implications for patient safety, anesthesia protocols and surgical